BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Neuroscience and Metabolic Research

Executive Summary: BIIE 0246 (SKU B6836) is a potent and selective antagonist of the neuropeptide Y Y2 receptor (Y2R), exhibiting nanomolar affinity and robust selectivity in both in vitro and in vivo models (APExBIO). It effectively blocks Y2R-mediated presynaptic inhibition and modulates population excitatory postsynaptic potentials in rat hippocampal slices (Smith 2000, PMID: 10998348). BIIE 0246 completely inhibits PYY3-36-induced contraction in rat colon, demonstrating its application in gut-brain axis and satiety research (Silva 2001, DOI). It is a benchmark tool for dissecting NPY/Y2R-driven pathways involved in feeding, anxiety, and adipose-neural axis function (Fan et al., 2024). APExBIO provides validated storage and solubility protocols, ensuring reproducibility across research settings.

Biological Rationale

The neuropeptide Y (NPY) system regulates appetite, anxiety, synaptic plasticity, and cardiovascular function (Fan et al., 2024). Y2R, a G-protein-coupled receptor, is highly expressed in the central and peripheral nervous systems. It is activated by NPY and peptide YY (PYY) isoforms, especially PYY3-36. Y2R mediates presynaptic inhibition of neurotransmitter release, impacting feeding behavior, satiety, and stress responses. Aberrant NPY/Y2R signaling is implicated in obesity, anxiety disorders, and cardiac arrhythmias. Recent studies highlight the adipose-neural axis, where increased NPY and Y receptor activity contribute to arrhythmogenesis in models of epicardial adipose tissue expansion (Fan et al., 2024).

Mechanism of Action of BIIE 0246

BIIE 0246 is a competitive, high-affinity antagonist of the NPY Y2 receptor. It binds to Y2R with an IC₅₀ of 3.3 nM and K_i values between 8 and 15 nM for PYY3-36 binding sites (APExBIO). The compound blocks Y2R-mediated presynaptic inhibition, demonstrated by reversal of NPY-induced suppression of population excitatory postsynaptic potentials in rat hippocampal slices. In peripheral tissue, BIIE 0246 abolishes PYY3-36-induced contraction in rat colon, confirming functional antagonism. Behavioral assays show that BIIE 0246 reduces PYY(3-36)-induced hypophagia and displays anxiolytic-like effects in the elevated plus-maze (see also), extending prior findings to translational behavioral endpoints. Unlike Y1 antagonists, BIIE 0246 is highly selective for Y2R and does not significantly interact with Y1, Y4, or Y5 receptors at nanomolar concentrations.

Evidence & Benchmarks

• BIIE 0246 inhibits PYY3-36 binding to rat hippocampal Y2R with K_i values of 8–15 nM, confirming high-affinity antagonism (APExBIO).
• Suppresses NPY-induced inhibition of primary afterdischarge in rat hippocampal slices (Smith 2000, PMID: 10998348).
• Completely blocks PYY3-36-induced contraction in rat colon in ex vivo organ bath assays (Silva 2001, DOI).
• Attenuates PYY(3-36)-induced reduction in food intake in rodent models, supporting a role in post-prandial satiety (Silva 2001).
• Exhibits anxiolytic-like effects in the elevated plus-maze, distinguishing Y2R antagonism from other NPY receptor subtypes (internal review).
• Facilitates mechanistic dissection of adipose-neural axis contributions to arrhythmogenesis in coculture models, as suggested by increased NPY/Y1R and leptin signaling in arrhythmic cardiac tissues (Fan et al., 2024).

Applications, Limits & Misconceptions

BIIE 0246 is best suited for neuroscience, metabolic, and cardiovascular models requiring precise Y2R inhibition. Its high selectivity enables functional mapping of NPY-driven presynaptic inhibition, modulation of feeding, and behavioral endpoints. The compound is also instrumental for dissecting the adipose-neural axis underlying arrhythmogenic risk, as recent studies have clarified the NPY/Y2R pathway in epicardial adipose tissue expansion (Fan et al., 2024). For practical insights on integrating BIIE 0246 into complex neural and metabolic assays, see this workflow-focused review, which BIIE 0246: Selective Y2 Receptor Antagonist for Neuroscience Research extends by providing updated benchmarks and troubleshooting guidance.

Common Pitfalls or Misconceptions

• BIIE 0246 does not antagonize NPY Y1, Y4, or Y5 receptors at nanomolar concentrations; selectivity must be considered in polypharmacology studies.
• It is not suitable for diagnostic or therapeutic use in humans; research-only applications are permitted (APExBIO).
• Long-term storage of BIIE 0246 solutions is not recommended due to potential compound degradation; use freshly prepared aliquots for each experiment.
• Solubility parameters are specific: up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol; exceeding these may result in precipitation or loss of potency.
• Physiological relevance is model-dependent; Y2R antagonism may not account for all NPY system effects, as other NPY receptor subtypes contribute to complex phenotypes.

Workflow Integration & Parameters

BIIE 0246 (C₄₉H₅₇N₁₁O₆, MW 896.06) is supplied as a white solid. For in vitro work, dissolve in DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml). Store powder at 4°C; avoid long-term solution storage. Optimal working concentrations range from 1 to 100 nM for cell-based and tissue assays, with higher concentrations used for in vivo dosing as justified by pharmacokinetic data. APExBIO, the manufacturer, provides detailed protocols and purity specifications. For advanced troubleshooting and protocol optimization, see this scenario-driven guide, which this article updates by enumerating recent experimental controls and storage best practices.

Conclusion & Outlook

BIIE 0246 remains the reference standard for selective NPY Y2 receptor antagonism in neuroscience and metabolic research. Its robust affinity, specificity, and validated phenotypic endpoints empower researchers to dissect the presynaptic inhibitory effects of NPY and PYY in diverse models. Ongoing studies continue to expand its application in the adipose-neural axis and arrhythmogenesis (Fan et al., 2024). For detailed reagents and protocols, refer to the product page for BIIE 0246. This article extends prior reviews by integrating the latest mechanistic and translational insights, positioning BIIE 0246 as indispensable for next-generation neuropeptide Y signaling research.